Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

A new study provides further evidence that the Rna Disruption Assay™ (RDA™) may be a useful tool to predict the clinical outcome of neoadjuvant chemotherapy in breast cancer patients. RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth […]

By |September 15th, 2016|Uncategorized|Comments Off on Further evidence RDA™ may predict clinical outcome of chemotherapy in Journal of the National Cancer Institute

April 2016 Newsletter

April Newsletter 2016
APRIL 27, 2016

In this issue:   an interview with the new CEO, patient accrual updates and more…

By |April 27th, 2016|Uncategorized|Comments Off on April 2016 Newsletter

Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO

Rna Diagnostics Inc. appoints
Dr. Jeremy Bridge-Cook President and CEO

Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive Officer of Rna Diagnostics Inc. […]

By |April 1st, 2016|Uncategorized|Comments Off on Rna Diagnostics Inc. appoints Dr. Jeremy Bridge-Cook President and CEO

RNA Disruption is a major biologic mechanism induced by multiple classes of chemotherapy drugs

Rna Diagnostics announces the publication of a study on February 24 2016 in the journal BMC Cancer entitled RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines. The study concludes that RNA disruption, as assessed by the RNA Disruption […]

By |March 10th, 2016|Uncategorized|Comments Off on RNA Disruption is a major biologic mechanism induced by multiple classes of chemotherapy drugs

Paul Lucas joins the Board of Directors at Rna Diagnostics Inc.

Rna Diagnostics Inc. announced today that Paul Lucas, an accomplished veteran of the Life Sciences industry, has joined the Company’s Board of Directors.

“Paul brings a wealth of proven business and Life Science innovation insight to Rna Diagnostics,” said Dr. Ken Pritzker, President and CEO of […]

By |February 18th, 2016|Uncategorized|Comments Off on Paul Lucas joins the Board of Directors at Rna Diagnostics Inc.

Rna Diagnostics “Breaking the Mold” at World Cancer Day event hosted by the Ontario Institute for Cancer Research and MaRS

The Ontario Institute for Cancer Research and MaRS Discovery District hosted an event for World Cancer Day under the banner of “Breaking the Mold: Rethinking the Cancer System.” Hosted by André Picard, Health Columnist of The Globe and Mail, the panel consisted of leading Cancer […]

By |February 12th, 2016|Uncategorized|Comments Off on Rna Diagnostics “Breaking the Mold” at World Cancer Day event hosted by the Ontario Institute for Cancer Research and MaRS

Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma in partnership with University of Guelph’s Ontario Veterinary College and supported by $100,000 grant from the Ontario Centres of Excellence

Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This […]

By |January 21st, 2016|Uncategorized|Comments Off on Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma in partnership with University of Guelph’s Ontario Veterinary College and supported by $100,000 grant from the Ontario Centres of Excellence

RDA™ Evolves into Platform Technology

While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management  of  treatments across multiple cancers. RDA is now being employed in clinical trials for […]

By |November 18th, 2015|Uncategorized|0 Comments

Newsletter Fall 2015

RDA™ Evolves into Platform Technology
While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management  of  treatments across multiple cancers. RDA is now being employed […]

By |October 29th, 2015|Uncategorized|0 Comments

First place for Rna Diagnostics in RESI Innovation Challenge

Rna Diagnostics was awarded first place in the RESI Innovation Challenge held in Boston, Massachusetts on September 16, 2015. The RESI Investor conference included an Innovation Challenge featuring 30 of the most innovative early stage life science companies selected from over 250 biotech, medtech and […]

By |September 21st, 2015|Uncategorized|0 Comments